Phase II Trial of Afatinib in Elderly Patients Aged Over 75 Years with EGFR Mutation Positive Non-Small Cell Lung Cancer

被引：1
作者：
Ko, R. [1 ]
Oizumi, S. [2 ]
Mizugaki, H. [3 ]
Fujita, Y. [2 ]
Harada, T. [4 ]
Takashina, T. [5 ]
Igawa, S. [6 ]
Watanabe, K. [7 ]
Hotta, T. [8 ]
Minemura, H. [9 ]
Saeki, S. [10 ]
Yagishita, S. [11 ]
Hamada, A. [11 ]
机构：
[1] Juntendo Univ, Grad Sch Med, Resp Med, Tokyo, Japan
[2] Natl Hosp Org Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan
[3] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan
[4] Jcho Hokkaido Hosp, Dept Resp Med, Sapporo, Hokkaido, Japan
[5] Iwamizawa Municipal Gen Hosp, Iwamizawa, Japan
[6] Kitasato Univ, Sch Med, Resp Med, Sagamihara, Kanagawa, Japan
[7] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[8] Shimane Univ, Fac Med, Izumo, Shimane, Japan
[9] Fukushima Med Univ, Pulm Med, Fukushima, Japan
[10] Kumamoto Univ, Kumamoto, Japan
[11] Natl Canc Ctr, Res Inst, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Afatinib; Adverse events; Elderly patients;
D O I：
10.1016/j.jtho.2019.08.1187
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.14-36
引用
收藏
页码：S568 / S568
页数：1
相关论文
共 50 条
  • [41] Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
    Nio, Yuta
    Ishida, Hiroo
    Matsumoto, Natsumi
    Kusumoto, Sojiro
    Kubota, Yutaro
    Tsunoda, Takuya
    Sasaki, Yasutsuna
    Fujita, Ken-ichi
    BMC PULMONARY MEDICINE, 2022, 22 (01)
  • [42] Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study
    Tamiya, Akihiro
    Tamiya, Motohiro
    Nishihara, Takashi
    Shiroyama, Takayuki
    Nakao, Keiko
    Tsuji, Taisuke
    Takeuchi, Naoko
    Isa, Shun-Ichi
    Omachi, Naoki
    Okamoto, Norio
    Suzuki, Hidekazu
    Okishio, Kyoichi
    Iwazaki, Ayano
    Imai, Kimie
    Hirashima, Tomonori
    Atagi, Shinji
    ANTICANCER RESEARCH, 2017, 37 (08) : 4177 - 4182
  • [43] Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non-Small-Cell Lung Cancer
    Cappuzzo, Federico
    Finocchiaro, Giovanna
    Grossi, Francesco
    Bidoli, Paolo
    Favaretto, Adolfo
    Marchetti, Antonio
    Valente, Maria Luisa
    Cseh, Agnieszka
    Clementi, Laura
    Massey, Dan
    Santoro, Armando
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (04) : 665 - 672
  • [44] A prospective observational study of postoperative adjuvant chemotherapy for non-small cell lung cancer in elderly patients (≥ 75 years)
    Tokujiro Yano
    Motoharu Hamatake
    Shoji Tokunaga
    Tatsuro Okamoto
    Koji Yamazaki
    Takashi Miura
    Takeshi Nagayasu
    Masami Sato
    Seiichi Fukuyama
    Kenji Sugio
    International Journal of Clinical Oncology, 2022, 27 : 882 - 888
  • [45] Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
    Aredo, Jacqueline, V
    Wakelee, Heather A.
    Neal, Joel W.
    Padda, Sukhmani K.
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 30
  • [46] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
    Paz-Ares, L.
    Tan, E. -H.
    O'Byrne, K.
    Zhang, L.
    Hirsh, V.
    Boyer, M.
    Yang, J. C. -H.
    Mok, T.
    Lee, K. H.
    Lu, S.
    Shi, Y.
    Lee, D. H.
    Laskin, J.
    Kim, D. -W.
    Laurie, S. A.
    Kolbeck, K.
    Fan, J.
    Dodd, N.
    Marten, A.
    Park, K.
    ANNALS OF ONCOLOGY, 2017, 28 (02) : 270 - 277
  • [47] Phase II Study of Docetaxel and Carboplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer
    Yoshimura, Naruo
    Kudoh, Shinzoh
    Kimura, Tatsuo
    Mitsuoka, Shigeki
    Kyoh, Shigenoir
    Tochino, Yoshihiro
    Asai, Kazuhisa
    Kodama, Toyoki
    Ichimaru, Yukikazu
    Yana, Takashi
    Hirata, Kazuto
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (03) : 371 - 375
  • [48] A prospective observational study of postoperative adjuvant chemotherapy for non-small cell lung cancer in elderly patients (≥ 75 years)
    Yano, Tokujiro
    Hamatake, Motoharu
    Tokunaga, Shoji
    Okamoto, Tatsuro
    Yamazaki, Koji
    Miura, Takashi
    Nagayasu, Takeshi
    Sato, Masami
    Fukuyama, Seiichi
    Sugio, Kenji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (05) : 882 - 888
  • [49] Survival of chemo-naive patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404
    Ninomiya, Takashi
    Nogami, Naoyuki
    Kozuki, Toshiyuki
    Harada, Daijiro
    Kubo, Toshio
    Ohashi, Kadoaki
    Ichihara, Eiki
    Kuyama, Shoichi
    Kudo, Kenichiro
    Bessho, Akihiro
    Sakugawa, Makoto
    Fujimoto, Nobukazu
    Aoe, Keisuke
    Minami, Daisuke
    Sugimoto, Keisuke
    Ochi, Nobuaki
    Takigawa, Nagio
    Hotta, Katsuyuki
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (08) : 1269 - 1276
  • [50] A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403
    Oda, Naohiro
    Hotta, Kastuyuki
    Ninomiya, Kiichiro
    Minami, Daisuke
    Ichihara, Eiki
    Murakami, Toshi
    Yokoyama, Toshihide
    Ichikawa, Hirohisa
    Chikamori, Kenichi
    Takigawa, Nagio
    Ochi, Nobuaki
    Harita, Shingo
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (06) : 1031 - 1038
12345